Steven Gelone
Director/Board Member bij NABRIVA THERAPEUTICS PLC
Vermogen: 20 454 $ op 31-07-2023
Profiel
Steven P.
Gelone is currently a Director at Nabriva Therapeutics Plc.
He previously held positions as a Director-Medical Affairs at Vicuron Pharmaceuticals LLC, a Director-Clinical Pharmacology at GSK Plc, and a Vice President-Clinical & Preclinical Development at Shire ViroPharma, Inc. He also served as the Chief Development Officer at Nabriva Therapeutics GmbH.
Additionally, Gelone was the Head-Clinical Research & Development at Spark Therapeutics, Inc. Gelone obtained his undergraduate and doctorate degrees from Temple University (Pennsylvania).
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
NABRIVA THERAPEUTICS PLC
0.45% | 31-01-2023 | 14 404 ( 0.45% ) | 20 454 $ | 31-07-2023 |
Actieve functies van Steven Gelone
| Bedrijven | Functie | Begin |
|---|---|---|
| NABRIVA THERAPEUTICS PLC | Director/Board Member | 01-03-2021 |
Eerdere bekende functies van Steven Gelone
| Bedrijven | Functie | Einde |
|---|---|---|
Nabriva Therapeutics GmbH
 Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | Chief Tech/Sci/R&D Officer | 30-06-2017 |
Shire ViroPharma, Inc.
 Shire ViroPharma, Inc. Pharmaceuticals: MajorHealth Technology Shire ViroPharma, Inc. develops and manufactures drugs. It offers treatment for prophylaxis of hereditary angioedema, as well as capsules for the treatment of antibiotic associated pseudomembranous colitis caused by Clostridium difficile infection (CDI) and enterocolitis. The company was founded by Claude H. Nash and Mark A. McKinlay in September 1994 and is headquartered in Exton, PA. | Corporate Officer/Principal | 01-01-2014 |
Vicuron Pharmaceuticals LLC
 Vicuron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Vicuron Pharmaceuticals LLC develops pharmaceutical products. It engages in discovering, developing, manufacturing, and commercializing vital medicine for seriously ill patients. The company offers anidulafungin drug, which prevents cell wall formation and other infectious fungi. It also offers antibiotic for the treatment of complicated skin and soft-tissue infections. The company was founded by Christopher T. Walsh in 1995 and is headquartered in King of Prussia, PA. | Chief Tech/Sci/R&D Officer | 01-01-2003 |
| GSK PLC | Chief Tech/Sci/R&D Officer | 01-01-2002 |
| SPARK THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | - |
Opleiding van Steven Gelone
| Temple University (Pennsylvania) | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| GSK PLC | Health Technology |
| NABRIVA THERAPEUTICS PLC | Health Technology |
| Bedrijven in privébezit | 4 |
|---|---|
Shire ViroPharma, Inc.
Shire ViroPharma, Inc. Pharmaceuticals: MajorHealth Technology Shire ViroPharma, Inc. develops and manufactures drugs. It offers treatment for prophylaxis of hereditary angioedema, as well as capsules for the treatment of antibiotic associated pseudomembranous colitis caused by Clostridium difficile infection (CDI) and enterocolitis. The company was founded by Claude H. Nash and Mark A. McKinlay in September 1994 and is headquartered in Exton, PA. | Health Technology |
Vicuron Pharmaceuticals LLC
Vicuron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Vicuron Pharmaceuticals LLC develops pharmaceutical products. It engages in discovering, developing, manufacturing, and commercializing vital medicine for seriously ill patients. The company offers anidulafungin drug, which prevents cell wall formation and other infectious fungi. It also offers antibiotic for the treatment of complicated skin and soft-tissue infections. The company was founded by Christopher T. Walsh in 1995 and is headquartered in King of Prussia, PA. | Health Technology |
Nabriva Therapeutics GmbH
Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | Health Technology |
Spark Therapeutics, Inc.
 Spark Therapeutics, Inc. BiotechnologyHealth Technology Spark Therapeutics, Inc. engages in the research, development, and commercialization of gene therapies. Its product portfolio intends to treat inherited retinal sickness, liver-mediated, and neurodegenerative diseases. The company was founded by Jean Bennett, Beverly Davidson, Katherine A. High, Jeffrey D. Marrazzo, J. Fraser Wright, and Jennifer Wellman on March 13, 2013 and is headquartered in Philadelphia, PA. | Health Technology |
